- Home
- TSAT vs ALT Comparison
TSAT vs ALT Comparison
Compare TSAT & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSAT
- ALT
- Stock Information
- Founded
- TSAT 1969
- ALT 1997
- Country
- TSAT Canada
- ALT United States
- Employees
- TSAT N/A
- ALT N/A
- Industry
- TSAT Metal Fabrications
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- TSAT Industrials
- ALT Health Care
- Exchange
- TSAT Nasdaq
- ALT Nasdaq
- Market Cap
- TSAT 394.3M
- ALT 327.4M
- IPO Year
- TSAT 1996
- ALT N/A
- Fundamental
- Price
- TSAT $26.12
- ALT $3.65
- Analyst Decision
- TSAT
- ALT Strong Buy
- Analyst Count
- TSAT 0
- ALT 6
- Target Price
- TSAT N/A
- ALT $17.40
- AVG Volume (30 Days)
- TSAT 88.5K
- ALT 2.4M
- Earning Date
- TSAT 11-13-2025
- ALT 11-11-2025
- Dividend Yield
- TSAT N/A
- ALT N/A
- EPS Growth
- TSAT N/A
- ALT N/A
- EPS
- TSAT N/A
- ALT N/A
- Revenue
- TSAT $358,754,564.00
- ALT $20,000.00
- Revenue This Year
- TSAT N/A
- ALT N/A
- Revenue Next Year
- TSAT N/A
- ALT $761,880.20
- P/E Ratio
- TSAT N/A
- ALT N/A
- Revenue Growth
- TSAT N/A
- ALT N/A
- 52 Week Low
- TSAT $10.11
- ALT $2.90
- 52 Week High
- TSAT $29.91
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- TSAT 64.63
- ALT 47.15
- Support Level
- TSAT $20.81
- ALT $3.54
- Resistance Level
- TSAT $27.83
- ALT $3.72
- Average True Range (ATR)
- TSAT 1.42
- ALT 0.15
- MACD
- TSAT 0.72
- ALT 0.02
- Stochastic Oscillator
- TSAT 78.63
- ALT 35.94
About TSAT Telesat Corporation
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.